EGFR and non-small cell lung carcinoma: Multiple pathway inhibition was the guiding strategy behind combining EGFR-TKIs with the anti-VEGF monoclonal antibody, bevacizumab, given its earlier success in improving overall survival in advanced NSCLC when given with chemotherapy (38).